CYP3A5 and oculocutaneous albinism type 1: However, the ICER was located to the left of the maximum acceptable ICER range, which indicated that the management was able to achieve graft survival without acute graft rejection and/or ATN for patients with CYP3A5*3 variant allele compared to CYP3A5*1 wildtype allele, but incurred an additional cost of MYR 44,8 307.70, rendering this approach not cost-effective in achieving graft survival without acute graft rejection and/or ATN in CYP3A5*3 compared to CYP3A5*1 polymorphism.